Your browser doesn't support javascript.
loading
Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal.
Sah, Shiv Kumar; Bhattarai, Pramod Raj; Shrestha, Anjana; Dhami, Deepak; Guruwacharya, Deepa; Shrestha, Renu.
Afiliación
  • Sah SK; Little Buddha College of Health Science, Purbanchal University, Minbhawan, Kathmandu, Nepal.
  • Bhattarai PR; National Tuberculosis Control Center, Bhaktapur, Nepal.
  • Shrestha A; Asian College for Advance Studies, Purbanchal University, Satdobato, Lalitpur, Nepal.
  • Dhami D; Asian College for Advance Studies, Purbanchal University, Satdobato, Lalitpur, Nepal.
  • Guruwacharya D; Asian College for Advance Studies, Purbanchal University, Satdobato, Lalitpur, Nepal.
  • Shrestha R; Asian College for Advance Studies, Purbanchal University, Satdobato, Lalitpur, Nepal.
Infect Drug Resist ; 13: 2911-2919, 2020.
Article en En | MEDLINE | ID: mdl-32903905
ABSTRACT

BACKGROUND:

Mycobacterium tuberculosis(MTB) remains a major public health problem worldwide, and emergence of drug-resistant TB has become a significant obstacle to effective TB control. However, the rate of MTB and rifampicin resistant-MTB (RR-MTB) in the Nepalese setting has not been studied extensively. Therefore, the present study aims to assess the rate of MTB and RR-MTB and further determine the factors associated with it.

METHODS:

A retrospective cross-sectional study, among national representative data of 990 consecutive presumptive TB resister of patients subjected to the GeneXpert test that presented to the tuberculosis referral hospital, was conducted over a one year period from February 2018 to January 2019. Significance for the difference for categorical data was performed by Chi-square test and factors associated with MTB and RR-MTB were assessed using binary logistic regression yielding OR with 95%CI.

RESULTS:

Of total 990 presumptive tuberculosis analyzed cases, median ages of the patients were 39±19.09 years and two-thirds of the patients were male 653 (66.0%). The estimated prevalence of MTB in presumptive TB patients was 13.8% (95%CI 11.88%-16.16%), and risk for MTB was significantly associated with previously treated patients OR 10.4 (P<0.001). The estimated prevalence of RR-MTB in MTB confirmed patients was 10.2% (4.97%-15.1%). Our study confirmed no association of RR-TB with age, sex, ethnicity, geographical diversity and previous history of treatment failure (P>0.05).

CONCLUSION:

The overall prevalence of MTB and RR-MTB was high in Nepalese study population,  and that being previously treated with anti-TB drug remained significant predictors for MTB; proactive measures are urgently needed to address the challenge of prompt diagnosis, early management and improved monitoring of treatment to limit the emergence drug-resistant MTB strains in the community.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2020 Tipo del documento: Article